表紙
市場調査レポート

デング熱:パイプライン分析

Dengue - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 192549
出版日 ページ情報 英文 204 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
デング熱:パイプライン分析 Dengue - Pipeline Review, H2 2015
出版日: 2015年07月15日 ページ情報: 英文 204 Pages
概要

デング熱は、蚊によって伝染するウイルス群によって引き起こされる疾患です。高熱、頭痛、関節痛や筋肉痛、嘔吐、発疹などの症状が見られます。場合によっては、デング出血熱に発展し、鼻や歯茎、皮下からの出血を引き起こすこともあります。治療には、鎮痛薬、補液療法、健康的な生活スタイルなどが含まれます。

当レポートでは、デング熱に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

デング熱の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Agilvax, Inc.
  • AltraVax Inc.
  • Arbovax, Inc.
  • BCI Pharma
  • BioDiem Ltd
  • Bioneer Corporation
  • Biotron Limited
  • CalAsia Pharmaceuticals, Inc.
  • Canopus BioPharma Incorporated
  • Cocrystal Pharma, Inc.
  • Codagenix, Inc.
  • GlaxoSmithKline Plc
  • Humabs BioMed SA
  • Immunotope, Inc.
  • Immunovaccine, Inc.
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Kineta, Inc.
  • Merck & Co., Inc.
  • Molplex Ltd.
  • Myelo Therapeutics GmbH
  • NanoViricides, Inc.
  • Panacea Biotec Limited
  • PaxVax
  • Prosetta Antiviral Inc.
  • Sanofi Pasteur SA
  • Sarepta Therapeutics, Inc.
  • SIGA Technologies, Inc.
  • SKAU Vaccines ApS
  • 武田薬品工業
  • TechnoVax, Inc.
  • Tekmira Pharmaceuticals Corp.
  • Themis Bioscience GmbH
  • United Therapeutics Corporation
  • VaxInnate Corporation
  • Visterra, Inc.

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • ABX-220
  • Antisense RNAi Oligonucleotide for Dengue
  • BG-323
  • CB-010
  • celgosivir hydrochloride
  • dengue (serotype DEN-2) vaccine
  • dengue (tetravalent) vaccine
  • dengue (tetravalent) vaccine
  • dengue (tetravalent) vaccine
  • dengue (tetravalent) vaccine
  • dengue (tetravalent) vaccine
  • dengue (tetravalent) vaccine
  • dengue (tetravalent) vaccine
  • dengue (tetravalent) vaccine
  • dengue (tetravalent) vaccine
  • dengue (tetravalent) vaccine
  • dengue (tetravalent) vaccine
  • dengue (tetravalent) vaccines
  • dengue rDEN1delta30, rDEN2/4delta30(ME), rDEN3delta30/31 and rDEN4delta30 (tetravalent) vaccine
  • dengue serotype 2 vaccine
  • dengue serotype DEN-1, DEN-2 vaccine
  • dengue serotype DEN-1 vaccine
  • dengue serotype DENV-2 vaccine
  • dengue serotypes 1,2,3,4 (tetravalent) vaccine
  • dengue serotypes 1,2,3,4 (tetravalent) vaccine
  • dengue serotypes 1,2,3,4 (tetravalent) vaccine
  • dengue serotypes 1,3,4 (trivalent) vaccine
  • dengue fever vaccine
  • dengue vaccine
  • dengue vaccine
  • dengue vaccine
  • dengue vaccine
  • dengue vaccine
  • dengue virus like particle vaccine
  • DengueCide
  • DiTU
  • DV-2DeltaGVII
  • DV-2DeltaLIG
  • DV-2G460P
  • ETX-101
  • FDX-000
  • fenretinide
  • FX-06
  • GBV-001
  • GBV-006
  • GREDEN/V1-4
  • LCTA-949
  • LVM-142
  • modipafant
  • Monoclonal Antibodies to Inhibit Virion, prM and E Proteins for Dengue
  • Monoclonal Antibody for Dengue
  • Monoclonal Antibody for Dengue
  • Myelo-001
  • PAV-866
  • PY-2
  • Recombinant Peptide to Inhibit Dengue Protease for Dengue
  • rOAS
  • RS-1137
  • RS-1142
  • RS-1145
  • RS-930
  • RS-961
  • Small Molecule for Dengue
  • Small Molecule for Dengue
  • Small Molecule for Dengue
  • Small Molecule to Agonize IRF-3 for Viral Infections
  • Small Molecule to Inhibit NS2B-NS3 Protease for Dengue and West Nile Virus Infection
  • Small Molecule to Inhibit NS3 Protease for Dengue and West Nile Virus Infections
  • Small Molecule to Inhibit NS5 for Dengue and Flavivirus Infections
  • Small Molecules for Dengue
  • Small Molecules for Dengue
  • Small Molecules Inhibiting M Protein for Dengue
  • Small Molecules to Activate AMPK for Dengue
  • Small Molecules to Inhibit Alpha-Glucosidase I and II for Viral Infections
  • Small Molecules to Inhibit Furin for Dengue
  • Small Molecules to Inhibit NS4B for Dengue
  • Small Molecules to Inhibit Pan Polymerase for Dengue
  • Small Molecules to Inhibit RNA Dependent RNA Polymerase for Dengue Virus Infections
  • Small Molecules to Inhibit Serine Protease for Viral Infections
  • ST-148
  • ST-324
  • ST-610
  • Synthetic Peptide for West Nile Virus and Dengue Virus Infections
  • TAK-003
  • TDEN-PIV
  • TVX-005
  • UV-4B
  • V-180
  • Viral PMO-X
  • VIS-513

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC6817IDB

Summary

Global Markets Direct's, 'Dengue - Pipeline Review, H2 2015', provides an overview of the Dengue's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dengue, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dengue and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Dengue
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Dengue and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Dengue products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Dengue pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Dengue
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Dengue pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Dengue Overview
  • Therapeutics Development
    • Pipeline Products for Dengue - Overview
    • Pipeline Products for Dengue - Comparative Analysis
  • Dengue - Therapeutics under Development by Companies
  • Dengue - Therapeutics under Investigation by Universities/Institutes
  • Dengue - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Dengue - Products under Development by Companies
  • Dengue - Products under Investigation by Universities/Institutes
  • Dengue - Companies Involved in Therapeutics Development
    • Abivax S.A.
    • Agilvax, Inc.
    • AltraVax Inc.
    • Arbovax, Inc.
    • BCI Pharma
    • BioDiem Ltd
    • Bioneer Corporation
    • Biotron Limited
    • CalAsia Pharmaceuticals, Inc.
    • Canopus BioPharma Incorporated
    • Cocrystal Pharma, Inc.
    • Codagenix, Inc.
    • GlaxoSmithKline Plc
    • Humabs BioMed SA
    • Immunotope, Inc.
    • Immunovaccine, Inc.
    • Inovio Pharmaceuticals, Inc.
    • Johnson & Johnson
    • Kineta, Inc.
    • Merck & Co., Inc.
    • Molplex Ltd.
    • Myelo Therapeutics GmbH
    • NanoViricides, Inc.
    • Panacea Biotec Limited
    • PaxVax
    • Prosetta Antiviral Inc.
    • Sanofi Pasteur SA
    • Sarepta Therapeutics, Inc.
    • SIGA Technologies, Inc.
    • SKAU Vaccines ApS
    • Takeda Pharmaceutical Company Limited
    • TechnoVax, Inc.
    • Tekmira Pharmaceuticals Corp.
    • Themis Bioscience GmbH
    • United Therapeutics Corporation
    • VaxInnate Corporation
    • Visterra, Inc.
  • Dengue - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ABX-220 - Drug Profile
    • Antisense RNAi Oligonucleotide for Dengue - Drug Profile
    • BG-323 - Drug Profile
    • CB-010 - Drug Profile
    • celgosivir hydrochloride - Drug Profile
    • dengue (serotype DEN-2) vaccine - Drug Profile
    • dengue (tetravalent) vaccine - Drug Profile
    • dengue (tetravalent) vaccine - Drug Profile
    • dengue (tetravalent) vaccine - Drug Profile
    • dengue (tetravalent) vaccine - Drug Profile
    • dengue (tetravalent) vaccine - Drug Profile
    • dengue (tetravalent) vaccine - Drug Profile
    • dengue (tetravalent) vaccine - Drug Profile
    • dengue (tetravalent) vaccine - Drug Profile
    • dengue (tetravalent) vaccine - Drug Profile
    • dengue (tetravalent) vaccine 3 - Drug Profile
    • dengue (tetravalent) vaccine 4 - Drug Profile
    • dengue (tetravalent) vaccines - Drug Profile
    • dengue [rDEN1delta30, rDEN2/4delta30(ME), rDEN3delta30/31 and rDEN4delta30] (tetravalent) vaccine - Drug Profile
    • dengue [serotype 2] vaccine - Drug Profile
    • dengue [serotype DEN-1, DEN-2] vaccine - Drug Profile
    • dengue [serotype DEN-1] vaccine - Drug Profile
    • dengue [serotype DENV-2] vaccine - Drug Profile
    • dengue [serotypes 1,2,3,4] (tetravalent) vaccine - Drug Profile
    • dengue [serotypes 1,2,3,4] (tetravalent) vaccine - Drug Profile
    • dengue [serotypes 1,2,3,4] (tetravalent) vaccine - Drug Profile
    • dengue [serotypes 1,3,4] (trivalent) vaccine - Drug Profile
    • dengue fever vaccine - Drug Profile
    • dengue vaccine - Drug Profile
    • dengue vaccine - Drug Profile
    • dengue vaccine - Drug Profile
    • dengue vaccine - Drug Profile
    • dengue vaccine 4 - Drug Profile
    • dengue virus like particle vaccine - Drug Profile
    • DengueCide - Drug Profile
    • DiTU - Drug Profile
    • DV-2DeltaGVII - Drug Profile
    • DV-2DeltaLIG - Drug Profile
    • DV-2G460P - Drug Profile
    • ETX-101 - Drug Profile
    • FDX-000 - Drug Profile
    • fenretinide - Drug Profile
    • FX-06 - Drug Profile
    • GBV-001 - Drug Profile
    • GBV-006 - Drug Profile
    • GREDEN/V1-4 - Drug Profile
    • LCTA-949 - Drug Profile
    • LVM-142 - Drug Profile
    • modipafant - Drug Profile
    • Monoclonal Antibodies to Inhibit Virion, prM and E Proteins for Dengue - Drug Profile
    • Monoclonal Antibody for Dengue - Drug Profile
    • Monoclonal Antibody for Dengue - Drug Profile
    • Myelo-001 - Drug Profile
    • PAV-866 - Drug Profile
    • PY-2 - Drug Profile
    • Recombinant Peptide to Inhibit Dengue Protease for Dengue - Drug Profile
    • rOAS - Drug Profile
    • RS-1137 - Drug Profile
    • RS-1142 - Drug Profile
    • RS-1145 - Drug Profile
    • RS-930 - Drug Profile
    • RS-961 - Drug Profile
    • Small Molecule for Dengue - Drug Profile
    • Small Molecule for Dengue - Drug Profile
    • Small Molecule for Dengue - Drug Profile
    • Small Molecule to Agonize IRF-3 for Viral Infections - Drug Profile
    • Small Molecule to Inhibit NS2B-NS3 Protease for Dengue and West Nile Virus Infection - Drug Profile
    • Small Molecule to Inhibit NS3 Protease for Dengue and West Nile Virus Infections - Drug Profile
    • Small Molecule to Inhibit NS5 for Dengue and Flavivirus Infections - Drug Profile
    • Small Molecules for Dengue - Drug Profile
    • Small Molecules for Dengue - Drug Profile
    • Small Molecules Inhibiting M Protein for Dengue - Drug Profile
    • Small Molecules to Activate AMPK for Dengue - Drug Profile
    • Small Molecules to Inhibit Alpha-Glucosidase I and II for Viral Infections - Drug Profile
    • Small Molecules to Inhibit Furin for Dengue - Drug Profile
    • Small Molecules to Inhibit NS4B for Dengue - Drug Profile
    • Small Molecules to Inhibit Pan Polymerase for Dengue - Drug Profile
    • Small Molecules to Inhibit RNA Dependent RNA Polymerase for Dengue Virus Infections - Drug Profile
    • Small Molecules to Inhibit Serine Protease for Viral Infections - Drug Profile
    • ST-148 - Drug Profile
    • ST-324 - Drug Profile
    • ST-610 - Drug Profile
    • Synthetic Peptide for West Nile Virus and Dengue Virus Infections - Drug Profile
    • TAK-003 - Drug Profile
    • TDEN-PIV - Drug Profile
    • TVX-005 - Drug Profile
    • UV-4B - Drug Profile
    • V-180 - Drug Profile
    • Viral PMO-X - Drug Profile
    • VIS-513 - Drug Profile
  • Dengue - Recent Pipeline Updates
  • Dengue - Dormant Projects
  • Dengue - Discontinued Products
  • Dengue - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Dengue, H2 2015
  • Number of Products under Development for Dengue - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Development by Companies, H2 2015 (Contd..1)
  • Number of Products under Development by Companies, H2 2015 (Contd..2)
  • Number of Products under Development by Companies, H2 2015 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Development by Companies, H2 2015 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
  • Dengue - Pipeline by Abivax S.A., H2 2015
  • Dengue - Pipeline by Agilvax, Inc., H2 2015
  • Dengue - Pipeline by AltraVax Inc., H2 2015
  • Dengue - Pipeline by Arbovax, Inc., H2 2015
  • Dengue - Pipeline by BCI Pharma, H2 2015
  • Dengue - Pipeline by BioDiem Ltd, H2 2015
  • Dengue - Pipeline by Bioneer Corporation, H2 2015
  • Dengue - Pipeline by Biotron Limited, H2 2015
  • Dengue - Pipeline by CalAsia Pharmaceuticals, Inc., H2 2015
  • Dengue - Pipeline by Canopus BioPharma Incorporated, H2 2015
  • Dengue - Pipeline by Cocrystal Pharma, Inc., H2 2015
  • Dengue - Pipeline by Codagenix, Inc., H2 2015
  • Dengue - Pipeline by GlaxoSmithKline Plc, H2 2015
  • Dengue - Pipeline by Humabs BioMed SA, H2 2015
  • Dengue - Pipeline by Immunotope, Inc., H2 2015
  • Dengue - Pipeline by Immunovaccine, Inc., H2 2015
  • Dengue - Pipeline by Inovio Pharmaceuticals, Inc., H2 2015
  • Dengue - Pipeline by Johnson & Johnson, H2 2015
  • Dengue - Pipeline by Kineta, Inc., H2 2015
  • Dengue - Pipeline by Merck & Co., Inc., H2 2015
  • Dengue - Pipeline by Molplex Ltd., H2 2015
  • Dengue - Pipeline by Myelo Therapeutics GmbH, H2 2015
  • Dengue - Pipeline by NanoViricides, Inc., H2 2015
  • Dengue - Pipeline by Panacea Biotec Limited, H2 2015
  • Dengue - Pipeline by PaxVax, H2 2015
  • Dengue - Pipeline by Prosetta Antiviral Inc., H2 2015
  • Dengue - Pipeline by Sanofi Pasteur SA, H2 2015
  • Dengue - Pipeline by Sarepta Therapeutics, Inc., H2 2015
  • Dengue - Pipeline by SIGA Technologies, Inc., H2 2015
  • Dengue - Pipeline by SKAU Vaccines ApS, H2 2015
  • Dengue - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015
  • Dengue - Pipeline by TechnoVax, Inc., H2 2015
  • Dengue - Pipeline by Tekmira Pharmaceuticals Corp., H2 2015
  • Dengue - Pipeline by Themis Bioscience GmbH, H2 2015
  • Dengue - Pipeline by United Therapeutics Corporation, H2 2015
  • Dengue - Pipeline by VaxInnate Corporation, H2 2015
  • Dengue - Pipeline by Visterra, Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Dengue Therapeutics - Recent Pipeline Updates, H2 2015
  • Dengue - Dormant Projects, H2 2015
  • Dengue - Dormant Projects (Contd..1), H2 2015
  • Dengue - Dormant Projects (Contd..2), H2 2015
  • Dengue - Dormant Projects (Contd..3), H2 2015
  • Dengue - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Dengue, H2 2015
  • Number of Products under Development for Dengue - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top